Lilly's Foundayo Demonstrates Cardiovascular Safety In Landmark Diabetes Study

Eli Lilly reported Phase 3 ACHIEVE-4 results showing that Foundayo (orforglipron) demonstrated cardiovascular safety while delivering sustained A1C reductions and weight loss in adults with type 2 diabetes and obesity or overweight. The positive late-stage clinical data support the drug's potential positioning in the large diabetes and obesity treatment markets, though the article excerpt does not provide detailed efficacy magnitudes or regulatory timing.